These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. AIDS research. Novel antibody response may explain HIV vaccine success. Cohen J Science; 2011 Sep; 333(6049):1560. PubMed ID: 21921167 [No Abstract] [Full Text] [Related]
3. The RV144 Thai HIV vaccine trial. Plotkin SA Hum Vaccin; 2010 Feb; 6(2):159. PubMed ID: 20431337 [No Abstract] [Full Text] [Related]
4. AIDS/HIV. Host controls of HIV neutralizing antibodies. Haynes BF; Verkoczy L Science; 2014 May; 344(6184):588-9. PubMed ID: 24812389 [TBL] [Abstract][Full Text] [Related]
5. AIDS/HIV. Converging on an HIV vaccine. Korber B; Gnanakaran S Science; 2011 Sep; 333(6049):1589-90. PubMed ID: 21921189 [No Abstract] [Full Text] [Related]
6. RV144: old vs. new. Weiner DB Hum Vaccin; 2010 Feb; 6(2):159-61. PubMed ID: 20431335 [No Abstract] [Full Text] [Related]
7. AIDS/HIV. A boost for HIV vaccine design. Burton DR; Weiss RA Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840 [No Abstract] [Full Text] [Related]
8. GP120: target for neutralizing HIV-1 antibodies. Pantophlet R; Burton DR Annu Rev Immunol; 2006; 24():739-69. PubMed ID: 16551265 [TBL] [Abstract][Full Text] [Related]
9. HIV. Escape artist par excellence. Cohen J Science; 2003 Mar; 299(5612):1505-8. PubMed ID: 12624245 [No Abstract] [Full Text] [Related]
10. The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development. O'Connell RJ; Kim JH; Excler JL Expert Rev Vaccines; 2014 Dec; 13(12):1489-500. PubMed ID: 25163695 [TBL] [Abstract][Full Text] [Related]
11. On the irrationality of rational design of an HIV vaccine in light of protein intrinsic disorder. Uversky VN Arch Virol; 2021 May; 166(5):1283-1296. PubMed ID: 33606110 [TBL] [Abstract][Full Text] [Related]
12. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1. Bower JF; Green TD; Ross TM Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849 [TBL] [Abstract][Full Text] [Related]
13. HIV vaccine design and the neutralizing antibody problem. Burton DR; Desrosiers RC; Doms RW; Koff WC; Kwong PD; Moore JP; Nabel GJ; Sodroski J; Wilson IA; Wyatt RT Nat Immunol; 2004 Mar; 5(3):233-6. PubMed ID: 14985706 [No Abstract] [Full Text] [Related]
14. Population-based analysis of HIV-1 antibodies reveals structural constraints that may inform vaccine design. Tobin SC AIDS; 2015 Sep; 29(15):N13. PubMed ID: 26237101 [No Abstract] [Full Text] [Related]
15. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope. Emini EA; Koff WC Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131 [No Abstract] [Full Text] [Related]
16. Exploring converse molecular mechanisms of anti-HIV-1 antibodies using a synthetic CXCR4 mimic. Haussner C; Möbius K; Eichler J Bioorg Med Chem Lett; 2012 Oct; 22(19):6099-102. PubMed ID: 22939235 [TBL] [Abstract][Full Text] [Related]